+ Watch SVNTQ
on My Watchlist
A biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets.
Slammed almost 50% because it couldn't find a buyer at it's already run-up speculated price. Remember it still has a fresh FDA approval of Krystexxa for arthritis, so the risk/reward at this point is very appealing.Potential for a quick pop from another (albeit lower) buyout price, or it can ride the Krystexxa sales for a while.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions